1-7 of 7
Tarec Christoffer El Galaly
Close
Sort by
Journal Articles

Metformin use and risk of myeloproliferative neoplasms - a Danish population-based case-control study

Clinical Trials & Observations
Daniel Tuyet Kristensen, Andreas Kiesbye Øvlisen, Lasse Hjort Jakobsen, Marianne Tang Severinsen, Louise Hur Hannig, Jørn Starklint, Morten Hagemann Hilsøe, Anders Pommer Vallentin, Mette Brabrand, Hans Carl Hasselbalch, Tarec Christoffer El Galaly, Anne Stidsholt Roug
Journal: Blood Advances
Blood Adv bloodadvances.2023012266.
https://doi.org/10.1182/bloodadvances.2023012266
Published: 2024
Includes: Supplemental data
Journal Articles

MRD-driven treatment with venetoclax-R2 in mantle cell lymphoma: the Nordic Lymphoma Group MCL7 VALERIA trial

Clinical Trials & Observations
Mats Jerkeman, Arne Kolstad, Martin Hutchings, Annika Pasanen, Leo Meriranta, Carsten Utoft Niemann, Rasmus Rask Kragh Jørgensen, Tarec Christoffer El-Galaly, Jon Riise, Sirpa Leppä, Jacob Haaber Christensen, Kristina Sonnevi, Lone Bredo Pedersen, Karin Fahl Wader, Ingrid Glimelius
Journal: Blood Advances
Blood Adv (2024) 8 (2): 407–415.
https://doi.org/10.1182/bloodadvances.2023011920
Published: 2024
Includes: Supplemental data
Journal Articles

Use of statins and risk of myeloproliferative neoplasms: a Danish nationwide case-control study

Clinical Trials & Observations
Daniel Tuyet Kristensen, Andreas Kisbye Øvlisen, Lasse Hjort Kyneb Jakobsen, Marianne Tang Severinsen, Louise Hur Hannig, Jørn Starklint, Morten Hagemann Hilsøe, Anders Pommer Vallentin, Mette Brabrand, Hans Carl Hasselbalch, Tarec Christoffer El-Galaly, Anne Stidsholt Roug
Journal: Blood Advances
Blood Adv (2023) 7 (14): 3450–3457.
https://doi.org/10.1182/bloodadvances.2023009784
Published: 2023
Includes: Supplemental data
Journal Articles

Risk of diabetes and the impact on preexisting diabetes in patients with lymphoma treated with steroid-containing immunochemotherapy

Joachim Baech, Marianne Tang Severinsen, Andreas K. Øvlisen, Henrik Frederiksen, Peter Vestergaard, Christian Torp-Pedersen, Judit Jørgensen, Michael Roost Clausen, Christian B. Poulsen, Peter Brown, Anne Ortved Gang, Robert Schou Pedersen, Karin Ekström Smedby, Sandra Eloranta, Lasse Hjort Jakobsen, Tarec Christoffer El-Galaly
Journal: Blood Advances
Blood Adv (2022) 6 (15): 4427–4435.
https://doi.org/10.1182/bloodadvances.2021006859
Published: 2022
Includes: Supplemental data
Journal Articles

A randomized trial of alendronate as prophylaxis against loss in bone mineral density following lymphoma treatment

Clinical Trials & Observations
Paw Jensen, Lasse Hjort Jakobsen, Martin Bøgsted, Joachim Baech, Simon Lykkeboe, Marianne Tang Severinsen, Peter Vestergaard, Tarec Christoffer El-Galaly
Journal: Blood Advances
Blood Adv (2022) 6 (8): 2549–2556.
https://doi.org/10.1182/bloodadvances.2021006330
Published: 2022
Includes: Supplemental data
Journal Articles

The MDM2 antagonist idasanutlin in patients with polycythemia vera: results from a single-arm phase 2 study

Clinical Trials & Observations
John Mascarenhas, Francesco Passamonti, Kate Burbury, Tarec Christoffer El-Galaly, Aaron Gerds, Vikas Gupta, Brian Higgins, Kathrin Wonde, Candice Jamois, Bruno Kovic, Ling-Yuh Huw, Sudhakar Katakam, Margherita Maffioli, Ruben Mesa, Jeanne Palmer, Marta Bellini, David M. Ross, Alessandro M. Vannucchi, Abdulraheem Yacoub
Journal: Blood Advances
Blood Adv (2022) 6 (4): 1162–1174.
https://doi.org/10.1182/bloodadvances.2021006043
Published: 2022
Includes: Supplemental data
Journal Articles

Impact of R-CHOP dose intensity on survival outcomes in diffuse large B-cell lymphoma: a systematic review

Clinical Trials & Observations
Edward J. Bataillard, Chan Yoon Cheah, Matthew J. Maurer, Arushi Khurana, Toby A. Eyre, Tarec Christoffer El-Galaly
Journal: Blood Advances
Blood Adv (2021) 5 (9): 2426–2437.
https://doi.org/10.1182/bloodadvances.2021004665
Published: 2021
Includes: Supplemental data